Entelos, a company specializing in predictive biosimulation technologies for drug discovery, development, and commercialization, has expanded its research collaboration with Johnson & Johnson Pharmaceutical R&D, to include multiple therapeutic areas over a five-year term.
During the first year of this new agreement, Entelos will dedicate several teams of research engineers and life scientists to support specific projects using its PhysioLab platforms on behalf of J&J and its affiliates.
J&J is already using Entelos’ models to validate targets, select biomarkers, and optimize clinical trials for type 2 diabetes, obesity, and anemia.
From our earliest agreement signed in November 1999, J&JPRD and its affiliates recognized the value in accurately simulating human biology in silico (in a computer) to rapidly validate novel drug targets, discover biomarkers, and evaluate and develop new drugs, stated James Karis, president and CEO of Entelos.
